The US FDA’s priority level for redaction and posting of biosimilar reviews may be hard to square with its approach to the follow-on products’ labeling and the agency's view of their potential to reduce drug prices.
Between March 2015 and July 2018, FDA licensed 12 biosimilars. However, action packages, which include various discipline reviews and other...






